UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  June 13, 2019

 

Millendo Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35890

 

45-1472564

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

110 Miller Avenue, Suite 100
Ann Arbor, Michigan

 

48104

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (734) 845-9000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

 

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value per share

 

MLND

 

The Nasdaq Capital Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

 

 

 

Item 5.02                            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 13, 2019, Dr. Pharis Mohideen notified the Company that he will be resigning from his position as Chief Medical Officer of Millendo Therapeutics, Inc. (the “Company”) effective July 12, 2019. Dr. Mohideen has informed the Company that he will be pursuing his career closer to his home in New Jersey, allowing him to spend more time with his family.

 

Item 8.01                                            Other Events.

 

On June 18, 2019, the Company issued a press release announcing Dr. Mohideen’s departure.  The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01                                            Financial Statements and Exhibits.

 

(d)    Exhibits

 

Exhibit
No.

 

Description

99.1

 

Press Released dated as of June 18, 2019

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MILLENDO THERAPEUTICS, INC.

 

 

Date: June 18, 2019

By:

/s/ Julia C. Owens, Ph.D.

 

 

Julia C. Owens, Ph.D.

 

 

President and Chief Executive Officer

 

3

Exhibit 99.1

 

 

Millendo Therapeutics Announces Departure of Chief Medical Officer

 

ANN ARBOR, Mich., June 18, 2019 — Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that Pharis Mohideen, M.D., is departing the company to pursue a career opportunity closer to his home in New Jersey, allowing him to spend more time with his family.

 

“ I am proud to have been Millendo’s Chief Medical Officer, and to have been part of the growth and success of the company for the past five years,” said Dr. Mohideen, “I leave behind an exceptional team, with a promising pipeline and a significant opportunity to have an impact in rare endocrine diseases. I look forward to following Millendo’s success in the years ahead.”

 

Julia C. Owens, Ph.D., President and CEO of Millendo commented, “Pharis has played a critical role in the advancement of our clinical-stage programs and supported the transformation of Millendo to a publicly traded biopharmaceutical company. I would like to thank him for his immense impact on the company and wish him success in the next chapter of his career.”

 

The company has initiated a search for a new CMO and is working with Dr. Mohideen on the details of his departure and transition plans for the organization. Ryan Zeidan, Ph.D., Senior Vice President of Development, will continue to lead the development activities at the company and in the interim will also oversee the medical function.

 

About Millendo Therapeutics, Inc.    
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.

 

 

Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie.ascher@sternir.com

 

Millendo Media Contact:

Betsy Yates

MacDougall

781-235-3094

byates@macbiocom.com

 

###